These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 24846238

  • 1. Cardiovascular effects of current and future anti-obesity drugs.
    Comerma-Steffensen S, Grann M, Andersen CU, Rungby J, Simonsen U.
    Curr Vasc Pharmacol; 2014 May; 12(3):493-504. PubMed ID: 24846238
    [Abstract] [Full Text] [Related]

  • 2. [Pharmacological therapy of obesity].
    Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [Abstract] [Full Text] [Related]

  • 3. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
    Isaacs D, Prasad-Reddy L, Srivastava SB.
    Am J Health Syst Pharm; 2016 Oct 01; 73(19):1493-507. PubMed ID: 27521241
    [Abstract] [Full Text] [Related]

  • 4. Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.
    Krentz AJ, Fujioka K, Hompesch M.
    Diabetes Obes Metab; 2016 Jun 01; 18(6):558-70. PubMed ID: 26936802
    [Abstract] [Full Text] [Related]

  • 5. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM, Nuffer W.
    Pharmacotherapy; 2014 Nov 01; 34(11):1174-86. PubMed ID: 25382096
    [Abstract] [Full Text] [Related]

  • 6. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes.
    Scheen AJ, Van Gaal LF.
    Lancet Diabetes Endocrinol; 2014 Nov 01; 2(11):911-22. PubMed ID: 24731666
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Tolerability and safety of the new anti-obesity medications.
    Hainer V, Aldhoon-Hainerová I.
    Drug Saf; 2014 Sep 01; 37(9):693-702. PubMed ID: 25096956
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Treatment of diabetes in patients with severe obesity.
    Scheen AJ.
    Biomed Pharmacother; 2000 Mar 01; 54(2):74-9. PubMed ID: 10759290
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. New medications for obesity management: changing the landscape of obesity treatment.
    Boulghassoul-Pietrzykowska N, Franceschelli J, Still C.
    Curr Opin Endocrinol Diabetes Obes; 2013 Oct 01; 20(5):407-11. PubMed ID: 23974768
    [Abstract] [Full Text] [Related]

  • 15. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
    Bays H.
    Expert Rev Cardiovasc Ther; 2010 Dec 01; 8(12):1777-801. PubMed ID: 20707765
    [Abstract] [Full Text] [Related]

  • 16. [The pharmacological treatment of obesity: past, present and future].
    Simonyi G, Pados G, Medvegy M, Bedros JR.
    Orv Hetil; 2012 Mar 11; 153(10):363-73. PubMed ID: 22370224
    [Abstract] [Full Text] [Related]

  • 17. The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database.
    Gorelik E, Gorelik B, Masarwa R, Perlman A, Hirsh-Raccah B, Matok I.
    Int J Obes (Lond); 2020 May 11; 44(5):1021-1027. PubMed ID: 32152496
    [Abstract] [Full Text] [Related]

  • 18. Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon.
    Srivastava G, Apovian C.
    Curr Obes Rep; 2018 Jun 11; 7(2):147-161. PubMed ID: 29504049
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.